Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence

Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence

IntroductionCurrent evidence shows that serum miR-371a-3p can identify disease recurrence in testicular germ cell tumour (TGCT) patients and correlates with tumour load. Despite convincing evidence showing the advantages of including miR-371a-3p testing to complement and overcome the classical serum...

Full description

Bibliographic Details
Main Authors: Ailsa J. Christiansen, João Lobo, Christian D. Fankhauser, Christian Rothermundt, Richard Cathomas, Aashil A. Batavia, Josias B. Grogg, Arnoud J. Templeton, Anita Hirschi-Blickenstorfer, Anja Lorch, Silke Gillessen, Holger Moch, Jörg Beyer, Thomas Hermanns
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
miRNA - microRNA
germ cell testicular cancer
serum biomarker
method optimization
clinical implementation
disease recurrence
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1056823/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1056823/full

Similar Items